germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...
germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...
germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Fundació</strong> <strong>Institut</strong> <strong>d'Investigació</strong><br />
<strong>en</strong> <strong>Ciències</strong> <strong>de</strong> la Salut<br />
Germans Trias i Pujol<br />
Future directions in the second‐line treatm<strong>en</strong>t of non‐small cell lung cancer.<br />
SEMIN ONCOL 2006; 33(1):S45‐S51.<br />
IF: 3,064<br />
Rosell R, Cecere F, Santarpia M, Reguart N, Taron M.<br />
Predicting the outcome of chemotherapy for lung cancer.<br />
CURR OPIN PHARMACOL 2006; 6(4):323‐331.<br />
IF: 6,916<br />
Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M.<br />
Treatm<strong>en</strong>t of non‐small‐cell lung cancer and pharmacog<strong>en</strong>omics: where we are and where we are going.<br />
CURR OPIN ONCOL 2006; 18(2):135‐143.<br />
IF: 3,571<br />
Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M.<br />
Usefulness of predictive tests for cancer treatm<strong>en</strong>t.<br />
BULL CANCER 2006 ;93 :E101‐8<br />
IF:<br />
Rosell R, Taron M, Galvez M, Pastor MC, Queralt C, Pradas A, Motia M, Perez M, Reguart N, Moran T, Sanchez JM,<br />
Amador ML, As<strong>en</strong>sio JL, Massuti B, Paz‐Ares L on behalf of the Spanish Lung Cancer Group.<br />
Determinación <strong>de</strong> las mutaciones <strong>de</strong>l receptor <strong>de</strong>l factor <strong>de</strong> crecimi<strong>en</strong>to epidérmico <strong>en</strong> paci<strong>en</strong>tes con cáncer <strong>de</strong><br />
pulmón no microcítico tratados únicam<strong>en</strong>te con erlotinib.<br />
FMC: Oncologia 2006;1:140‐9<br />
IF:<br />
Rosell R, Taron M, Reguart N, Isla D, Moran T.<br />
Epi<strong>de</strong>rmal growth factor receptor activation: how exon 19 and 21 mutations changed our un<strong>de</strong>rstanding of the<br />
pathway.<br />
CLIN CANCER RES 2006 Dec 15;12(24):7222‐31.<br />
IF: 6,177<br />
Rosell R.<br />
Circumv<strong>en</strong>ting resistance to EGFR‐specific cancer therapy.<br />
Adv Lung Cancer 2006;7:3‐7<br />
IF:<br />
Rosell, R.<br />
Optimizing chemotherapy in non‐small cell lung cancer.<br />
Am J Cancer 2006;5:211‐2<br />
IF:<br />
Salazar R, Vilar E, Martinez MP, Sastre J, Alonso V, Sevilla MI, Villabona C, Marazuela M, Castellano D, Diaz JA, Abad<br />
A, Blanco C, Llanos M.<br />
Preliminary results for 2001‐2005 of the Spanish Registry of the Gastro<strong>en</strong>teropancreatic NETs.<br />
NEUROENDOCRINOLOGY 2006; 83(1):46‐46.<br />
IF: 2,68<br />
Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balana C.<br />
A case of c‐kit positive high‐gra<strong>de</strong> stromal <strong>en</strong>dometrial sarcoma responding to Imatinib Mesylate.<br />
GYNECOL ONCOL 101(3):545‐547.<br />
Pàgina 71/177
Change language